A review of antibiotic therapy for pelvic inflammatory disease

Duarte, Rui; Fuhrich, Daniele Geras; Ross, Jonathan

doi:10.1016/j.ijantimicag.2015.05.004

Cited by 46 publications

(48 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pelvic inflammatory disease (PID) is an infection disorder, which affects the female upper genital tract [4]. It usually occurs as an ascending infection from the endocervix and vagina, resulting in endometritis, salpingitis, tubo-ovarian abscess, parametritis, oophoritis and/or pelvic peritonitis [1,4].…”

Section: Introductionmentioning

confidence: 99%

“…It usually occurs as an ascending infection from the endocervix and vagina, resulting in endometritis, salpingitis, tubo-ovarian abscess, parametritis, oophoritis and/or pelvic peritonitis [1,4]. There is a considerable amount of agents implicated in PID's pathology, including sexually transmitted organisms such as Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT) [4]. Microorganisms found in the vaginal flora (e.g.…”

Section: Introductionmentioning

confidence: 99%

“…Microorganisms found in the vaginal flora (e.g. anaerobes, Gardnerella vaginalis, Haemophilus influenza, enteric Gram-negative rods and Streptococcus agalactiae) could also result in PID [4]. The high impact of PID in public health is related with its high incidence, sequelae of infertility, ectopic pregnancy and chronic pelvic pain [4].…”

Section: Introductionmentioning

confidence: 99%

“…anaerobes, Gardnerella vaginalis, Haemophilus influenza, enteric Gram-negative rods and Streptococcus agalactiae) could also result in PID [4]. The high impact of PID in public health is related with its high incidence, sequelae of infertility, ectopic pregnancy and chronic pelvic pain [4]. It is most common in young, nulliparous and sexually active women with multiple partners [4].…”

Section: Introductionmentioning

confidence: 99%

“…The high impact of PID in public health is related with its high incidence, sequelae of infertility, ectopic pregnancy and chronic pelvic pain [4]. It is most common in young, nulliparous and sexually active women with multiple partners [4].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Sexually Transmitted Infections, Pelvic Inflammatory Disease, and the Role from Intrauterine Devices: Myth or Fact?

Carvalho¹,

Botelho²,

Mauro³

et al. 2017

J Biomedical Sci

View full text Add to dashboard Cite

Connections among Intra Uterine Devices (IUD), Sexually Transmitted Diseases (STDs) and Pelvic inflammatory disease (PID) still bring doubts for health professionals; Our goal is to understand better these associations. We searched the PubMed database for articles including evidence about these topics. A common outcome found is the superiority of levonorgestrel (LNG) IUD over NOVA T (copper) device regarding clinical performance and PID rates. The modern IUDs do not elevate the risk of getting PID; however this risk is higher when a patient has a STI at the time she gets an IUD. It is wise requiring a STI test, principally for cervicitis, before placing an IUD. The epidemiologic data suggests this management mainly for woman with a new sexual partner, or with multiple sexual partners, and under age 25. It is also correct inserting an IUD and test for STI at the same day: if positive results come, antibiotics can be used. Old papers usually show a higher risk for PID in IUD users, an outcome not found in recent researches that have improved methodology and therefore are more reliable. However, the investigation concerning the STI and cervicitis remain as an important point to investigate before decision to IUD use.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Sexually Transmitted Infections, Pelvic Inflammatory Disease, and the Role from Intrauterine Devices: Myth or Fact?

Carvalho¹,

Botelho²,

Mauro³

et al. 2017

J Biomedical Sci

View full text Add to dashboard Cite

show abstract

ZY5301 Tablet vs Placebo for Treatment of Chronic Pelvic Pain After Pelvic Inflammatory Disease

Teng,

Li,

Yang

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceChronic pelvic pain (CPP) is the main sequela of pelvic inflammatory disease (PID), with no established treatment. ZY5301 tablets, an effective part preparation extracted from Ajuga decumbens Thunb. (jingucao), are being tested as a treatment for CPP caused by PID.ObjectiveTo evaluate whether ZY5301 tablets are effective and safe for CPP treatment in women with PID.Design, Setting, and ParticipantsThis placebo-controlled double-blind, dose-parallel, phase 2 randomized clinical trial was conducted in 9 hospitals in China. Female participants with CPP after PID were enrolled between October 16, 2020, and August 31, 2021. The data analysis was performed between December 2021 and March 2022.InterventionsParticipants were randomized 1:1:1 to receive ZY5301 300 mg/d, ZY5301 600 mg/d, or placebo orally 3 times a day for 12 weeks.Main Outcomes and MeasuresVisual analog scale (VAS) scores were the main measure used to evaluate the efficacy of ZY5301 in reducing CPP. The evaluation end points for VAS score included changes in mean weekly VAS score from baseline, area under the VAS score-time curve, pain remission (VAS score of 0 and 1) rate, and median time to pain remission. Safety was evaluated by the occurrence of treatment-emergent and treatment-related adverse events.ResultsIn total, 180 women were randomly assigned, and 177 were included in the efficacy analysis; thus, the full analysis set included 60 participants in the ZY5301 mg/d group (mean [SD] age, 37.4 [8.1] years), 58 in the ZY5301 600 mg/d group (mean [SD] age, 37.1 [7.9] years), and 59 in the placebo group (mean [SD] age, 38.9 [7.3] years). Participant characteristics at baseline were similar among the groups. After 12 weeks of treatment, the mean (SD) change in VAS score from the baseline was −2.1 (1.7) points, −3.5 (1.5) points, and −3.8 (1.7) points in the placebo, ZY5301 300 mg/d, and ZY5301 600 mg/d groups, respectively (P &lt; .001). The pain remission rates at week 12 were 43.3% and 53.5% in the ZY5301 300 mg/d and ZY5301 600 mg/d groups, respectively, a significant difference compared with the placebo group (11.9%; P &lt; .001). All the other end points showed similar improvements. The ZY5301 600 mg/d group had better efficacy than the ZY5301 300 mg/d group, but the difference was not significant. The safety analysis revealed no significant differences among groups.Conclusions and RelevanceThese findings show that ZY5301 tablet is efficacious for the relief of CPP with acceptable tolerability.Trial RegistrationClinicalTrials.gov Identifier: NCT05460546

show abstract

Genital Mycoplasmas

Ljubin‐Sternak

2018

Diagnostics to Pathogenomics of Sexually Transmitted Infections

View full text Add to dashboard Cite

A review of antibiotic therapy for pelvic inflammatory disease

Cited by 46 publications

References 42 publications

Sexually Transmitted Infections, Pelvic Inflammatory Disease, and the Role from Intrauterine Devices: Myth or Fact?

Sexually Transmitted Infections, Pelvic Inflammatory Disease, and the Role from Intrauterine Devices: Myth or Fact?

ZY5301 Tablet vs Placebo for Treatment of Chronic Pelvic Pain After Pelvic Inflammatory Disease

Genital Mycoplasmas

Contact Info

Product

Resources

About